anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Fraud Exposure

Framework collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 6,793
Current window 4,921-4,950
Pages 227
Rows per page 30
Framework: Fraud Exposureclear collectionreset all
18 30 60

Framework

4,921-4,950 of 6,793

filter-aware
140
The slide uses a quote from a consultant to challenge the validity of the company's (Harmony) data submitted to the FDA.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
143
The slide uses a ClinicalTrials.gov entry as evidence of a 'buried' or incomplete study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
151
Uses anecdotal evidence from Facebook patient support groups to highlight a safety gap.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
154
The slide uses a 'villain critique' style to frame the FDA's approval as flawed and the drug's safety as compromised.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
158
The slide uses direct quotes from FDA clinical reviews to highlight the discrepancy between pre-approval assumptions and post-approval safety signals.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses a direct quote from an FDA clinical review to demonstrate a lack of oversight regarding a specific medical signal.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
178
The slide highlights a potential discrepancy between official FDA reporting and actual event timing, suggesting either database lag or manufacturer reporting delays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
215
The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
222
The slide uses FDA biometrics review data to challenge the efficacy timeline of the drug Wakix (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
224
The slide uses a 'red flag' argument to suggest data manipulation or p-hacking via sample size adjustment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
230
The slide uses a redacted document image to illustrate the lack of transparency in the FDA's review process compared to the EMA's.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
233
The slide uses a combination of a pie chart and two tables to substantiate claims of trial design flaws.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
238
The slide highlights a discrepancy between the trial paper's log-scale chart and the actual linear-scale data, suggesting data manipulation or misleading presentation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
240
The slide uses ClinicalTrials.gov record history to demonstrate a 'red flag' in trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
241
The slide uses red text for emphasis on specific criticisms (dose response, centre effect).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
243
The slide uses red boxes and text annotations to highlight specific data points (M6 for ESS, M12 for cataplexy) that contradict expected outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit